syngo.CT CaScoring vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

syngo.CT CaScoring

by Siemens Healthineers

ElucidVivo A.3

by Elucid

AI Verdict

Tool A, syngo.CT CaScoring, is specifically designed for the quick quantification and visualization of calcified coronary lesions, primarily for cardiovascular risk assessment using metrics like the Agatston score. In contrast, Tool B, ElucidVivo A.3, offers a more comprehensive analysis of arterial plaque composition and stability, including calcifications, lipid-rich necrotic core, and matrix, to aid in atherosclerosis patient stratification and treatment decisions. While both analyze cardiac CTs for plaque, Tool B provides a deeper, more detailed characterization beyond just calcium scoring.

Choose syngo.CT CaScoring if…

Choose syngo.CT CaScoring if your primary need is a rapid and accurate quantification of calcified coronary lesions for initial cardiovascular risk assessment. This tool excels at providing standardized metrics like the Agatston Score, volume, and calcium mass, making it ideal for routine screening and comparing patient scores to healthy reference groups.

View syngo.CT CaScoring →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require a comprehensive, in-depth analysis of arterial plaque composition and stability to guide advanced patient stratification and treatment optimization. This system is particularly suited for understanding vulnerable plaque characteristics, such as Lipid-Rich Necrotic Core (LRNC), and deriving functional insights like FFRct, which are crucial for personalized management of atherosclerosis.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	syngo.CT CaScoring	ElucidVivo A.3
Pricing	Contact for pricing	Unknown
Deployment	Integrated with Siemens CT scanner systems; operates as a post-processing application on the multi-user syngo.via client/server platform.	Cloud and on-premise secure deployment.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

syngo.CT CaScoring

syngo.CT CaScoring benefits from deep integration within the established Siemens syngo.via platform, which has been shown to improve workflow efficiency and user experience in cardiac CT reading. While ElucidVivo A.3 offers advanced visualization, its more intricate analysis might imply a steeper learning curve, whereas syngo.CT CaScoring is designed for streamlined routine tasks within a familiar ecosystem.

Clinical Value

ElucidVivo A.3

ElucidVivo A.3 offers a more advanced and comprehensive clinical assessment by quantifying arterial plaque composition and stability, including Lipid-Rich Necrotic Core, validated against ground-truth histology. This provides deeper, predictive insights for atherosclerosis patient stratification and treatment optimization, and it also derives FFRct, which goes beyond the traditional calcium scoring offered by Tool A.

Pricing & Value

syngo.CT CaScoring

While both tools require contacting the vendor for current pricing, Tool A provides historical pricing information and explicitly states a one-time license purchase model, offering a degree of transparency not present for Tool B. This limited insight into its pricing structure gives Tool A a slight edge in value transparency.

Enterprise Readiness

syngo.CT CaScoring

Siemens (Tool A) is a well-established global enterprise with a comprehensive suite of digital solutions, robust support infrastructure, and proven integration capabilities within large hospital systems. Elucid Bioimaging (Tool B), while offering PACS/EMR integration, is a significantly smaller company, which typically implies less extensive enterprise-level support and scalability compared to a major vendor like Siemens.

Innovation

ElucidVivo A.3

ElucidVivo A.3 demonstrates greater innovation by providing a unique, histologically validated quantitative analysis of arterial plaque composition and stability, including the quantification of Lipid-Rich Necrotic Core and the derivation of FFRct from CT angiography. This offers more advanced, predictive insights for personalized atherosclerosis management, moving beyond the more traditional calcium scoring offered by Tool A.

Support & Docs

syngo.CT CaScoring

Siemens (Tool A) is a large, established healthcare technology company with a well-documented global support infrastructure and comprehensive product documentation. In contrast, specific details regarding the breadth and depth of support and documentation for ElucidVivo A.3 (Tool B) are not readily available, making it difficult to assess its offerings in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	syngo.CT CaScoring	ElucidVivo A.3
Name	syngo.CT CaScoring	ElucidVivo A.3
Company	Siemens Medical Solutions USA	Elucid
Description	AI-powered image analysis software for quick quantification and accurate visualization of calcified coronary lesions from CT scans, aiding in cardiovascular risk assessment and documentation.	FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology.
Tagline	AI-powered quantification and visualization of coronary calcifications	Visualize Lesion-level Plaque Composition
Categories	Cardiology AI	Cardiology AI, Radiology & Imaging AI
Key Features	Quick quantification of calcified coronary lesions; Accurate visualization of calcified coronary lesions; Calculation of Agatston Score, volume, and calcium mass; Assessment of plaque burden in total and per coronary artery (RCA, LM, LAD, CX); Automatic highlighting of coronary calcifications; User-modifiable threshold for score calculation (default 130 HU); Comparison of patient score to healthy reference groups (e.g., MESA study); Calculation of 'Coronary Age'	AI-powered quantitative analysis of arterial plaque; Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections; Aids in stratifying patients with atherosclerosis; Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity; Validated on ground-truth histology

Videos

Demos, reviews, and walkthroughs featuring syngo.CT CaScoring and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical focus and utility of each tool?

syngo.CT CaScoring primarily focuses on the quick quantification and accurate visualization of calcified coronary lesions from CT scans, aiding in cardiovascular risk assessment by calculating scores like Agatston, volume, and calcium mass. ElucidVivo A.3, on the other hand, provides quantitative analysis of arterial plaque composition and stability from CT angiography, assisting in atherosclerosis patient stratification and optimizing treatment decisions by quantifying Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications.

What specific quantitative metrics do these tools provide?

syngo.CT CaScoring calculates the Agatston Score, volume, and calcium mass, and assesses plaque burden in total and per coronary artery (RCA, LM, LAD, CX). ElucidVivo A.3 objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, and also derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.

How do these tools integrate into existing imaging infrastructure and workflows?

syngo.CT CaScoring is integrated with Siemens CT scanner systems and operates as a post-processing application on the multi-user syngo.via client/server platform. ElucidVivo A.3 is a software application, likely on-premise or cloud-based, that integrates with PACS/EMR systems.

What is the basis of validation for the analytical results provided by each tool?

syngo.CT CaScoring allows for the comparison of patient scores to healthy reference groups, such as the MESA study, and has undergone non-clinical integration and functional testing. ElucidVivo A.3's quantitative analysis of arterial plaque composition and stability is validated against ground-truth histology.

What are the implications for patient stratification and treatment optimization with each tool?

syngo.CT CaScoring helps assess cardiovascular risk by quantifying calcified coronary lesions and comparing them to reference groups, which can be a prognostic indicator for atherosclerotic coronary heart disease. ElucidVivo A.3 aids in stratifying patients with atherosclerosis and optimizing treatment decisions by providing detailed visualization and measurement of plaque characteristics, including those validated against histology, and deriving FFRct.